Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

17.51 +1.27 (+7.82%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Volume	1,712,563
Open	18.11
Bid (Size)	16.10 (100)
Ask (Size)	17.71 (300)
Prev. Close	16.24
Today's Range	17.01 - 18.14
52wk Range	7.800 - 19.71
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

February 24, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

February 24, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+6.9%	+6.9%
1 Month	+6.6%	+6.6%
3 Month	-7.8%	-7.8%
6 Month	+45.7%	+45.7%
1 Year	+40.6%	+40.6%

More News

Bicara Therapeutics to Participate in Upcoming Investor Conferences

February 23, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

February 19, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 05, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

January 12, 2026

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12

December 15, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

December 06, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025

December 01, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

November 20, 2025

Via Investor Brand Network

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

November 20, 2025

From BioMedWire

Via GlobeNewswire

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 10, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

Via Investor Brand Network

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

Via FinancialNewsMedia

These stocks that are showing activity before the opening bell on Monday. ↗

October 13, 2025

Via Chartmill

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

October 13, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

Via Benzinga

Bicara Therapeutics to Participate in Upcoming Investor Conferences

August 27, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

June 11, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 04, 2025

Via Benzinga

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

June 01, 2025

From Bicara Therapeutics Inc.

Via GlobeNewswire

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? ↗

May 23, 2025

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

May 23, 2025

Via Chartmill

Frequently Asked Questions

Is Bicara Therapeutics Inc. - Common Stock publicly traded?

Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Bicara Therapeutics Inc. - Common Stock trade on?

Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?

The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market

What is the current price of Bicara Therapeutics Inc. - Common Stock?

The current price of Bicara Therapeutics Inc. - Common Stock is 17.51

When was Bicara Therapeutics Inc. - Common Stock last traded?

The last trade of Bicara Therapeutics Inc. - Common Stock was at 02/25/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.